Energenesis to Spotlight Diabetic Foot Ulcer Drug at EWMA 2026

Energenesis to Spotlight Diabetic Foot Ulcer Drug at EWMA 2026

By, Admin 30 April 2026

Clinical-stage biotech Energenesis Biomedical Co., Ltd. is taking its lead wound-care candidate to a global stage.

The company will present new clinical application insights for ENERGI-F703DFU at the European Wound Management Association (EWMA) 2026 Annual Conference, scheduled for May 5–7 in Bremen, Germany.

What to Expect at EWMA 2026?

Energenesis will deliver a focused, case-based presentation:

  • Title: ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foot Ulcers — Clinical Case Sharing
  • Date & Time: May 6, 2026 | 14:35–14:50 CEST
  • Session: New Tech Industry Symposium

The company plans to showcase real-world clinical insights on how the drug candidate may support wound closure and improve healing outcomes in chronic diabetic foot ulcers (DFUs).

The Drug: ENERGI-F703DFU

ENERGI-F703DFU is not a typical wound-care product. It’s being positioned as a first-in-class small-molecule topical therapy.

Mechanism of Action

  • Targets cellular energy pathways
  • Increases intracellular ATP levels in epithelial cells
  • Promotes cell regeneration and intrinsic repair mechanisms

This approach shifts the focus from external wound management to internal cellular activation.

Clinical Progress: Moving Through Phase III

The candidate is currently in a Phase III trial (NCT05930210) across Taiwan and the United States.

Trial Design Highlights

  • Patient type: Grade 1–2 DFUs (Wagner classification)
  • Ulcer size: 1.5 cm² to 25 cm²
  • Treatment duration: 16 weeks

These criteria are based on earlier Phase II findings.

Phase II Results (Signal That Matters)

  • Complete closure rate: 36.7% (treatment group)
  • Control group: 9.1%
  • Statistical significance: P < 0.05

That delta is what pushed the program into late-stage development.

Why Diabetic Foot Ulcers Are a High-Stakes Problem?

DFUs are more than slow-healing wounds. They are a major clinical and economic burden.

  • High risk of infection
  • Frequent hospitalizations
  • Leading cause of lower-limb amputations

Despite existing care protocols, effective pharmacological options remain limited—creating space for differentiated therapies like ENERGI-F703DFU.

Pipeline Snapshot: Beyond DFUs

Energenesis is building a broader portfolio around cellular energy restoration:

  • ENERGI-F701: Alopecia treatment (Phase II completed)
  • ENERGI-F703DFU: Diabetic foot ulcer gel (Phase III)
  • ENERGI-F703EB: Epidermolysis bullosa therapy (Phase II-ready; orphan designations from U.S. Food and Drug Administration and European Medicines Agency)
  • ENERGI-F705PD: Parkinson’s disease candidate (pre-Phase II)

The common thread: activating intrinsic repair via cellular energy pathways.

Strategic Takeaway

Energenesis is betting on a simple but underexplored idea, fix the cell’s energy system, and healing follows.

If Phase III data confirms earlier results, ENERGI-F703DFU could:

  • Become a first-in-class therapy in DFU treatment
  • Reduce reliance on supportive care alone
  • Open a new category in wound healing pharmacology

Bottom Line

EWMA 2026 won’t just be a presentation—it’s a visibility moment. Energenesis is moving from early promise to late-stage validation. Now the question is whether the clinical signal holds at scale.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!